A recent randomized study revealed a startling reality in modern healthcare: half of all women presenting with vaginal symptoms who test negative for infections are still prescribed unnecessary antimicrobial treatments. Nanopath, a Cambridge-based diagnostics innovator, aims to eliminate this clinical guesswork. The company recently secured $25 million in Series B funding to finalize its 15-minute, point-of-care vaginitis test designed specifically for the exam room.

Prioritizing the Clinic Over Consumer Kits

The investment round was co-led by Norwest and the Medtech Convergence Fund, with strategic backing from Labcorp Ventures, bringing the startup’s total capital raised to over $46 million. Co-CEOs Alison Burklund and Amogha Tadimety are pursuing a distinct market strategy: while competitors focus on direct-to-consumer at-home testing, Nanopath is building a solution integrated into clinical workflows and covered by insurance.

The tools clinicians use to diagnose infections in women during a visit really haven’t been innovated on in over 50 years, limited to microscopy, urine dips, pregnancy tests.

Burklund notes that traditional microscopy is often inaccurate, yet the industry has largely pivoted to home-based testing. Nanopath is taking a different path, leveraging existing insurance codes that offer over 90% coverage. This approach ensures accessibility for patients who might otherwise be deterred by out-of-pocket costs, aligning with data showing that a majority of women still prefer in-clinic consultations for diagnostic procedures.

Strategic Focus: From Vaginitis to UTIs

Born from PhD research at Dartmouth, Nanopath’s proprietary optical biosensing technology identifies DNA and RNA without the need for traditional PCR amplification. After extensive consultations with medical professionals, the founders pivoted away from hospital settings—where sales cycles are notoriously long—to focus on the high-volume, high-need area of vaginitis.

  • Vaginitis: Chosen for its massive market size, with over 10 million annual office visits, and a clear regulatory pathway.
  • Urinary Tract Infections: The company’s secondary focus, which recently earned FDA Breakthrough Device designation.

The founders emphasize that the neglect of these conditions is a systemic issue, noting that if such infections affected men at the same rate, diagnostic solutions would have evolved decades ago.

Efficiency in the Exam Room

For a physician balancing 30 patients a day, time is the most valuable commodity. Nanopath’s 15-minute test is engineered to provide actionable results before the patient leaves the office, potentially saving clinicians the 8 to 10 hours per week they currently spend on follow-up calls. By providing immediate, accurate data, the test aims to reduce the high rate of inappropriate prescriptions and the subsequent return visits that burden the healthcare system.

While competitors like Cepheid offer molecular panels, Nanopath’s focus on speed—targeting a 15-minute turnaround—seeks to provide a transformative advantage. Dr. Paul Nyirjesy of the Jefferson Vulvovaginal Health Center notes that such rapid, accurate diagnostics would allow for targeted treatment while the patient is still present, significantly improving the standard of care.

Scaling for the Future

With a lean team of 24 employees, Nanopath has utilized approximately $4.5 million in non-dilutive grants from the NIH and NSF to reach this stage. The new funding will support manufacturing scale-up and a pivotal FDA 510(k) clinical study across multiple sites. As the company prepares for its next phase, the founders remain committed to their original mission: ensuring that their diagnostic technology reaches the communities where it is needed most, rather than remaining confined to the lab.